ModifiedEmblemHealthPolicy AHS-G2011

Diagnostic Testing of Iron Homeostasis and Metabolism — Lab Benefit Program (LBM)

Defines coverage criteria for laboratory testing of iron homeostasis (eg, serum ferritin, transferrin saturation, hepcidin) under EmblemHealth's Lab Benefit Program and describes clinical/scientific background relevant to test use; applies to providers submitting claims to EmblemHealth.

Policy Summary

PayerEmblemHealth

PolicyDiagnostic Testing of Iron Homeostasis and Metabolism — Lab Benefit Program (LBM)

Policy CodePolicy AHS-G2011

Change TypeCoverage clarification and template transfer

Effective DateMar 1, 2023

Next Review Date

Key ActionMeasure serum transferrin saturation only for specified clinical indications; testing of asymptomatic individuals does not meet coverage.

SourceLink

POLICY UPDATE CHANGES

Removed "(using serum iron and serum iron binding capacity measurements)" from Coverage Criteria; measurement of serum transferrin saturation now explicitly MEETS COVERAGE CRITERIA in specified situations.

Updated Coverage Criteria to clarify that testing outside of addressed conditions is not allowed, specifically testing of asymptomatic individuals does not meet coverage.

Transferred policy content to individual company-branded template.

Lab Benefit Program (LBM) expanded to include EmblemHealth HMO/PPO (Non-City) Commercial, Medicare and Medicaid plans effective 10/1/2024.

Addition of new Note 2 to define first-degree relative.

2/2025most recent policy update date listed

10/01/2024LBM expansion effective

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

84% sensRET-He predictive performance

10,000extreme ferritin level cited

7 codesprocedure codes listed

Coverage Criteria for Iron Homeostasis Testing

Serum ferritin coverage

Covered when ALL of the following indications apply:

ANY of the following

Measurement of serum ferritin levels MEETS COVERAGE CRITERIA for the evaluation of an individual with abnormal hemoglobin and/or hematocrit levels (e.g., suspected anemia).
Measurement of serum ferritin levels MEETS COVERAGE CRITERIA for the evaluation and monitoring of iron overload disorders.
Measurement of serum ferritin levels MEETS COVERAGE CRITERIA for individuals with symptoms of hemochromatosis (see Note 1).
Measurement of serum ferritin levels MEETS COVERAGE CRITERIA for individuals who are first-degree relatives (see Note 2) of persons with confirmed hereditary hemochromatosis (HH).
Measurement of serum ferritin levels MEETS COVERAGE CRITERIA for the evaluation of individuals with liver disease.
Measurement of serum ferritin levels MEETS COVERAGE CRITERIA for the evaluation of hemophagocytic lymphohistiocytosis (HLH) and Still Disease.
Measurement of serum ferritin levels MEETS COVERAGE CRITERIA in males with secondary hypogonadism.
Measurement of serum ferritin levels MEETS COVERAGE CRITERIA for the evaluation and monitoring of patients with chronic kidney disease who are receiving or being considered for receiving treatment for anemia.
Measurement of serum ferritin levels MEETS COVERAGE CRITERIA for individuals on iron therapy.
When monitoring is indicated, serum ferritin may be measured at a frequency of every 1 to 3 months as clinically appropriate.

Transferrin saturation coverage

Covered when ANY of the following clinical situations apply:

ANY of the following

Measurement of serum transferrin saturation MEETS COVERAGE CRITERIA for the evaluation of iron overload in individuals with symptoms of hemochromatosis (see Note 1).
Measurement of serum transferrin saturation MEETS COVERAGE CRITERIA for the evaluation of iron overload in individuals who are first-degree relatives (see Note 2) of persons with confirmed hereditary hemochromatosis (HH).
Measurement of serum transferrin saturation MEETS COVERAGE CRITERIA for the evaluation of iron deficiency anemia.

Non-covered tests

The following tests DO NOT MEET COVERAGE CRITERIA due to insufficient published evidence of clinical benefit:

ANY of the following

Measurement of ferritin or transferrin levels, including transferrin saturation, for indications not listed in the policy (see Coverage Criteria) DOES NOT MEET COVERAGE CRITERIA.
Serum hepcidin testing, including immunoassays, DOES NOT MEET COVERAGE CRITERIA.
The use of GlycA testing to measure or monitor transferrin or other glycosylated proteins DOES NOT MEET COVERAGE CRITERIA.

Guideline-based criteria

Guideline-referenced testing approaches and numeric cutoffs cited in source guidance:

AGA ferritin cutoff in anemia: In patients with anemia, the AGA recommends using a ferritin cutoff of 45 ng/mL rather than 15 ng/mL to diagnose iron deficiency; consider CRP, transferrin saturation, or soluble transferrin receptor in inflammatory or CKD contexts.

ACG hereditary hemochromatosis evaluation: In patients without acute hepatitis, test for hereditary hemochromatosis with serum iron level, transferrin saturation, and serum ferritin as recommended by the ACG.

WHO ferritin thresholds: WHO recommends age- and condition-specific ferritin cutoffs (examples: infants and preschool children: <12 μg/L in apparently healthy individuals, <30 μg/L with infection/inflammation; adults: <15 μg/L in apparently healthy individuals, <70 μg/L with infection/inflammation); risk-of-overload thresholds: ferritin >150 μg/L females, >200 μg/L males, and >500 μg/L with inflammation.

Diagnostic Testing - LBM

This policy is administered under the Lab Benefit Program (LBM); applicable procedure codes and reimbursement guidance include:

Reimbursement Policy: Diagnostic Testing of Iron Homeostasis and Metabolism is administered under the Lab Benefit Program (LBM).

Applicable procedure codes referenced in the policy include CPT/HCPCS codes: 82728 (Ferritin), 83540 (Iron), 83550 (Iron binding capacity), 84466 (Transferrin), 84999 (Unlisted chemistry procedure), 0024U (GlycA), and 0251U (Hepcidin-25, ELISA).

Coverage Criteria Updates

Recent coverage updates and clarifications documented in the revision history:

Measurement of serum transferrin saturation MEETS COVERAGE CRITERIA when performed for the specified clinical indications listed in the policy. (Revision note: removed the parenthetical phrase referencing SI/SIBC measurement methods to clarify acceptable methods.)

Measurement of ferritin or transferrin levels, including transferrin saturation, DOES NOT MEET COVERAGE for all other situations not addressed in the policy; testing asymptomatic individuals outside addressed conditions is excluded.

Operational clarification: the policy was updated to require that individuals be symptomatic for the indications provided; being symptomatic in general is insufficient for coverage unless tied to the listed indications.

Coding and Procedure Codes

Referenced coding guidancemixed

No codes listed

Tests discussed (no codes listed in this section)mixed

No codes listed

Procedure codes referencedCPT | HCPCS | mixed

82728	Ferritin
83540	Iron
83550	Iron binding capacity
84466	Transferrin
84999	Unlisted chemistry procedure
0024U	Glycosylated acute phase proteins (GlycA), nuclear magnetic resonance spectroscopy
0251U	Hepcidin-25, enzyme-linked immunosorbent assay (ELISA), serum or plasma Proprietary test: Intrinsic Hepcidin IDx TM Test

No explicit codes in this segmentmixed

No codes listed

Ferritin diagnostic cutoffs (per guidelines)

AGA anemia ferritin cutoffUse 45 ng/mL rather than 15 ng/mL to diagnose iron deficiency in patients with anemia (AGA recommendation).

WHO infant/preschool cutoffsInfants (0–23 months) and preschool (24–59 months): ferritin <12 µg/L in apparently healthy individuals; <30 µg/L with infection/inflammation.

WHO adult/adolescent cutoffAdolescents and adults (≥5 years): ferritin <15 µg/L in apparently healthy individuals (WHO 2020).

ASH monitoring noteSerum ferritin should be checked frequently (every 3–6 weeks) to calculate running averages due to temporal variability (ASH recommendation).

Ferritin cutoffs and inflammation-adjusted thresholds

Provider Billing, Authorization, and Reimbursement Actions

Billing Rule

Billing and claims guidance

Current billing and claims payment policies apply to all EmblemHealth products unless otherwise noted. Providers must follow applicable billing, coding, and claims payment policies (including CPT® guidelines, NCCI, MUE edits, and other industry-standard coding edits) when submitting claims for diagnostic testing of iron homeostasis and metabolism. If billing or reimbursement policies are not followed, claims may be denied and/or previously paid claims may be recouped.

Follow current billing and claims payment policies for all products.
Use industry-standard coding edits (CPT, CMS/NCCI, MUE).
Failure to follow billing or reimbursement policies may result in claim denial or recoupment.

Note

Reimbursement Policy LBM

Use this Reimbursement Policy (AHS-G2011) as the Lab Benefit Program (LBM) guidance for diagnostic testing of iron homeostasis and metabolism. Ensure claims are submitted under the LBM where applicable and follow any product-specific LBM rules or provider manual instructions. Updates to policy or billing procedures will be posted on EmblemHealth reimbursement policy webpages and communicated via provider manuals and newsletters.

Definitions and Test Descriptions

Selected abbreviations/terms

SFSerum ferritin (SF).

TfRTransferrin receptor (TfR).

TSATTransferrin saturation (TSAT).

HHHereditary hemochromatosis (HH).

HLHHemophagocytic lymphohistiocytosis (HLH).

GlycA — biomarker of chronic inflammation

GlycA definitionGlycA is a biomarker of chronic inflammation measured by NMR that integrates signals from N-acetyl methyl groups of glycoproteins but cannot distinguish contributions of individual proteins (Otvos et al., 2015).

Policy Summary

PayerEmblemHealth

PolicyDiagnostic Testing of Iron Homeostasis and Metabolism — Lab Benefit Program (LBM)

Policy CodePolicy AHS-G2011

Change TypeCoverage clarification and template transfer

Effective DateMar 1, 2023

Next Review Date

Key ActionMeasure serum transferrin saturation only for specified clinical indications; testing of asymptomatic individuals does not meet coverage.

SourceLink

On This Page

WHO inflammation-adjusted thresholdsIn individuals with infection/inflammation: ferritin cutoffs may be raised (examples: preschool <30 µg/L; adults up to <70 µg/L in presence of inflammation).

ICCAMS inflammatory-state cutoffIn inflammatory states, ferritin <100 ng/mL may define iron deficiency; reticulocyte Hb <29 pg or serum hepcidin <20 pg/L also suggest deficiency if available (ICCAMS).

ECCO remission vs active diseaseECCO: use ferritin ~30 µg/L in remission; with active inflammation consider cutoffs up to 100 µg/L for defining iron deficiency in IBD contexts.

Expanded plan coverage effective date

LBM expansion effective dateLab Benefit Program (LBM) expanded to include EmblemHealth HMO/PPO (Non-City) Commercial, Medicare and Medicaid plans effective 10/01/2024.

This document is the Reimbursement Policy for Diagnostic Testing of Iron Homeostasis and Metabolism under the Lab Benefit Program (LBM).
Follow product-specific LBM billing rules and provider manual guidance.
Monitor EmblemHealth reimbursement policy webpages and provider communications for updates.

Prior Authorization

Coverage Authorization Summary

Measurement of serum transferrin saturation meets coverage criteria only in the specific clinical situations outlined in this policy. Measurement of ferritin or transferrin levels, including transferrin saturation, does not meet coverage for situations not addressed in the Coverage Criteria (for example, routine testing of asymptomatic individuals or situations not specified under covered indications).

Measurement of serum transferrin saturation meets coverage only for the clinical indications specified in this policy.
Testing ferritin or transferrin (including transferrin saturation) is not covered for other situations, including asymptomatic screening.
Providers should ensure clinical documentation supports the specific covered indication when submitting claims.

Assay noteGlycA measurement requires deconvolution of overlapping NMR signals; it shows lower imprecision and variability than hsCRP but cannot quantify individual glycoproteins such as transferrin.

Clinical implicationGlycA cannot be used to accurately determine concentrations of specific proteins (eg, transferrin) due to signal overlap and glycan heterogeneity.

Hepcidin — definition and assay notes

Hepcidin definitionHepcidin is a circulating peptide hormone that regulates iron homeostasis.

Assay typesAssays include competitive ELISA and high-performance liquid chromatography–tandem mass spectrometry (HPLC‑MS/MS / LC‑MS/MS).

Analytic performanceHPLC‑MS/MS methods report intra‑CVs <3% and inter‑CVs <6% with low relative error across storage and freeze–thaw conditions (Chen et al., 2019).

RET‑He — reticulocyte hemoglobin equivalent

RET‑He definitionRET‑He is the reticulocyte hemoglobin equivalent, a CBC‑derived measure of reticulocyte hemoglobin content used as a marker of iron deficiency.

Clinical relevanceRET‑He correlates with serum iron, ferritin, and TSAT and may predict response to IV iron and prognosis in conditions like heart failure (Tahara et al., 2022).

Use caseConsider RET‑He when ferritin and TSAT are limited by inflammation; changes in RET‑He during hospitalization were associated with outcomes in heart failure patients.

Laboratory developed tests (LDTs) — regulatory note

LDT regulatory statusLaboratory‑developed tests (LDTs) are regulated by CMS under CLIA '88 as high‑complexity tests and are not approved/cleared by the FDA for clinical use.

Laboratory responsibilityIndividual laboratories must validate and perform LDTs in‑house per CLIA requirements prior to clinical use.

FDA noteFDA clearance or approval is not currently required for clinical use of LDTs, but LDTs are not FDA‑approved/cleared.

Transferrin saturation / NTBI / LPI — definitions and significance

TSAT >85% implicationTransferrin saturation (TSAT) values exceeding 85% can lead to circulating non‑transferrin‑bound iron (NTBI) and labile plasma iron (LPI), increasing risk for endocrine and cardiac iron accumulation.

DefinitionsNTBI = non‑transferrin‑bound iron; LPI = labile plasma iron — both are markers associated with iron toxicity risk.

Monitoring considerationTSAT, NTBI, and LPI are useful research metrics for iron toxicity risk but are not yet suitable for routine monitoring in place of imaging (eg, liver iron concentration or cardiac T2*).

First‑degree relative — Note 2 reference

First‑degree relative (Note 2)Policy references a newly added Note 2 to define ‘first‑degree relative’ for hereditary hemochromatosis evaluation; the detailed definition is recorded in Note 2 of the policy.

Context of useFirst‑degree relatives are referenced as an indication for ferritin and transferrin testing in hereditary hemochromatosis workup per coverage criteria.

Administrative noteAddition of Note 2 occurred during policy updates (recorded in revision history).